Patrick A Baeuerle Selected Research

Bispecific Antibodies

1/2022	A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
6/2013	Targeting T cells to tumor cells using bispecific antibodies.
6/2012	Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer.
10/2011	Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
5/2011	Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.
8/2010	Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
6/2009	Bispecific T-cell engaging antibodies for cancer therapy.
11/2007	Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
3/2007	CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
8/2003	Bispecific antibodies for polyclonal T-cell engagement.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrick A Baeuerle Research Topics

Disease

52	Neoplasms (Cancer) 01/2022 - 04/2002
26	Bites and Stings (Sting) 01/2018 - 04/2005
12	Carcinoma (Carcinomatosis) 01/2020 - 07/2002
8	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 05/2011
7	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2003
6	Lymphoma (Lymphomas) 06/2013 - 03/2007
5	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 06/2003
5	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 05/2005
4	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 10/2006
4	Melanoma (Melanoma, Malignant) 10/2011 - 02/2006
4	Ovarian Neoplasms (Ovarian Cancer) 11/2006 - 06/2003
3	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 06/2009
3	Leukemia 06/2012 - 06/2009
3	Rheumatoid Arthritis 03/2009 - 07/2004
3	Autoimmune Diseases (Autoimmune Disease) 03/2009 - 07/2003
2	Persistent Infection 01/2018 - 01/2006
2	Philadelphia Chromosome 04/2016 - 12/2012
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2014 - 01/2014
2	Residual Neoplasm 12/2012 - 06/2011
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2012 - 05/2005
2	Breast Neoplasms (Breast Cancer) 11/2010 - 05/2005
2	Lung Diseases (Lung Disease) 02/2007 - 02/2007
2	Renal Cell Carcinoma (Grawitz Tumor) 02/2006 - 05/2005
2	Neointima 02/2005 - 04/2004
1	Triple Negative Breast Neoplasms 01/2021
1	Human Influenza (Influenza) 01/2017
1	B-Cell Leukemia (Leukemia, B Cell) 06/2013
1	Pancreatitis 11/2010
1	Tics (Tic) 10/2010
1	Disease Progression 01/2010
1	Lung Neoplasms (Lung Cancer) 05/2009
1	Celiac Disease (Celiac Sprue) 03/2009
1	Stomach Neoplasms (Stomach Cancer) 01/2009
1	Adenocarcinoma 01/2009

Drug/Important Bio-Agent (IBA)

27	Epithelial Cell Adhesion MoleculeIBA 01/2020 - 06/2003
19	AntibodiesIBA 06/2013 - 07/2003
14	AntigensIBA 01/2022 - 07/2003
13	blinatumomabIBA 01/2018 - 08/2008
10	Bispecific AntibodiesIBA 01/2022 - 08/2003
9	CytokinesIBA 01/2019 - 02/2006
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2006
7	Immunoglobulin G (IgG)IBA 11/2010 - 06/2003
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 04/2007
6	Surface Antigens (Surface Antigen)IBA 01/2021 - 02/2006
6	Single-Chain AntibodiesIBA 01/2018 - 04/2005
6	EpitopesIBA 01/2011 - 12/2006
6	Monoclonal AntibodiesIBA 08/2010 - 06/2003
4	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2017
4	adecatumumabIBA 11/2010 - 10/2006
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 02/2007 - 02/2006
3	Interleukin-2 (IL2)IBA 10/2011 - 02/2006
3	Peptides (Polypeptides)IBA 06/2009 - 05/2005
3	Propidium (Propidium Iodide)IBA 01/2009 - 06/2003
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 01/2020
2	ErbB Receptors (EGF Receptor)IBA 01/2017 - 07/2010
2	AMG 330IBA 06/2014 - 01/2014
2	Pharmaceutical PreparationsIBA 12/2012 - 04/2007
2	Carcinoembryonic AntigenIBA 01/2012 - 05/2009
2	Chondroitin Sulfate ProteoglycansIBA 10/2011 - 08/2010
2	HMW-MAAIBA 10/2011 - 08/2010
2	Complement System Proteins (Complement)IBA 11/2010 - 08/2010
2	EdrecolomabIBA 11/2010 - 07/2002
2	Cell Adhesion MoleculesIBA 10/2010 - 07/2009
2	Complementary DNA (cDNA)IBA 07/2008 - 02/2006
2	CD3 ComplexIBA 01/2008 - 04/2007
2	CollagenIBA 07/2007 - 12/2006
2	Sirolimus (Rapamycin)FDA Link 02/2005 - 04/2004
1	MesothelinIBA 01/2021
1	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2021
1	Serum AlbuminIBA 01/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2020
1	Human immunodeficiency virus 1 gp120 proteinIBA 01/2018
1	Antiviral Agents (Antivirals)IBA 01/2018
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 06/2014
1	LectinsIBA 06/2014
1	PasotuxizumabIBA 12/2012
1	VaccinesIBA 06/2012
1	CD19 AntigensIBA 06/2011
1	Immunoglobulin IsotypesIBA 05/2011
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 10/2010
1	AgarIBA 10/2010
1	Cetuximab (Erbitux)FDA Link 07/2010
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2010
1	Phospholipases (Phospholipase)IBA 05/2009
1	Rituximab (Mabthera)FDA Link 03/2009
1	CTLA-4 AntigenIBA 02/2009
1	EnzymesIBA 01/2009
1	DNA (Deoxyribonucleic Acid)IBA 01/2009
1	Adenylate KinaseIBA 01/2009
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2009

Therapy/Procedure

22	Therapeutics 01/2022 - 04/2002
7	Drug Therapy (Chemotherapy) 01/2014 - 05/2005
6	Immunotherapy 01/2017 - 01/2006
2	Injections 07/2006 - 04/2005
1	Castration 01/2021
1	Duration of Therapy 01/2018
1	Transplantation 01/2013
1	Intraperitoneal Injections 12/2012
1	Immunomodulation 05/2011
1	Prostatectomy (Retropubic Prostatectomy) 01/2010